![]() These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. More information can be found at Forward-looking Statements We are delivering on our commitments as we build an innovative company dedicated to advancing global health. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. ![]() (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. Wachtell, Lipton, Rosen & Katz served as legal advisor to Bausch Health in this transaction.īausch Health Companies Inc. Synergy's flagship product, TRULANCE® (plecanatide) is a once-daily tablet approved for adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), and its investigational compound, dolcanatide, is an incremental peptide with established proof-of-concept studies in multiple GI conditions. Subject to approval of the Bankruptcy Court and the satisfaction or waiver of certain other closing conditions, the transaction is expected to close shortly after receipt of approval of the sale. The hearing to approve the sale is scheduled for March 1, 2019. Under the terms of the agreement, Bausch Health served as the stalking horse bidder in a sale process, which Synergy conducted pursuant to Section 363 of the Bankruptcy Code and court-approved bidding procedures. At that time, Bausch Health entered into a definitive agreement to acquire certain assets of Synergy. Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court"). Code (the "Bankruptcy Code") with the U.S. Additionally, dolcanatide, an investigational incremental peptide that has established proof of concept studies in a host of GI conditions, will be a welcome addition to our early stage pipeline."Īs previously announced, in December 2018, Synergy filed a voluntary petition (the "Chapter 11 Petition") for reorganization under Chapter 11 of the U.S. "With our team's expertise in GI and primary care, we will strengthen our already formidable portfolio of innovative irritable bowel syndrome solutions with the addition of TRULANCE®. We are excited to acquire the assets of Synergy, which we believe will strategically enhance our Salix Pharmaceuticals business and supplement our organic growth in gastroenterology," said Joseph C. "As we continue to transform Bausch Health, we are now pivoting to offense with research investments and strategic acquisitions that augment our core businesses. (NASD: SGYP) ("Synergy") for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into with the Company (as described below). (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that the Company was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals Inc. 26, 2019 /PRNewswire/ - Bausch Health Companies Inc. Public Reporting on Product and Service Safety Issuesīausch Health and Synergy to Seek Bankruptcy Court Approval of Sale on March 1, 2019. ![]() ![]() Global Quality Management System (GQMS).Submitting a Supplier Diversity Profile.Auditing, Monitoring and Risk Assessments.Dermatology Products/Aesthetics Devices. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |